CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2017		Dec. 31, 2016
CURRENT ASSETS
Cash and cash equivalents	$ 23,816		$ 22,088
Available for sale securities	915		627
Trade accounts and grants receivable, net	206		446
Landlord receivable	0		200
Receivable from affiliates, net (Note 9)	2,807		511
Prepaid expenses and other current assets	1,513		1,777
Total current assets	29,257		25,649
Property, plant and equipment, net	4,992	[1]	5,529
Deferred license fees	90		118
Deposits and other long-term assets	977		1,031
Equity method investment in OncoCyte, at fair value (Note 4)	87,312		0
Equity method investment in Asterias, at fair value (Note 5)	73,942		100,039
Intangible assets, net	8,646	[1]	10,206
TOTAL ASSETS	205,216		142,572
CURRENT LIABILITIES
Accounts payable and accrued liabilities	6,947	[1]	7,144
Capital lease liability, current portion	0		202
Promissory notes, current portion	124		99
Related party convertible debt, net of discount	1,070		833
Deferred license and subscription revenue, current portion	679		572
Total current liabilities	8,820		8,850
LONG-TERM LIABILITIES
Deferred revenues, net of current portion	231		308
Deferred rent liabilities, net of current portion	66		50
Lease liability	1,344		1,386
Capital lease, net of current and other liabilities	0		310
Related party convertible debt, net of discount	1,077		1,032
Promissory notes, net of current portion	95		120
Other long term liabilities	9		8
Deferred tax liability	3,877		0
TOTAL LIABILITIES	15,519		12,064
Commitments and contingencies (Note 13)
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2017 and December 31, 2016	0		0
Common shares, no par value, 150,000 shares authorized; 110,860 shares issued and outstanding and 103,396 issued and 102,776 shares outstanding as of March 31, 2017 and December 31, 2016, respectively	333,997		317,878
Accumulated other comprehensive income (loss)	408		(738)
Accumulated deficit	(147,033)		(196,321)
Treasury stock at cost: no shares as of March 31, 2017; 620 shares as of December 31, 2016	0		(2,891)
BioTime, Inc. shareholders' equity	187,372		117,928
Noncontrolling interest	2,325		12,580
Total shareholders' equity	189,697		130,508
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY	$ 205,216		$ 142,572

[1] Reflects the effect of the OncoCyte Deconsolidation.